Wenjuan Shen

Wenjuan Shen

Auto-generated profile, based on publicly available information

Wenjuan Shen

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WSWenjuan Shen
Wenjuan Shen
BJBao Jin
Bao Jin
YPYujia Pan
Yujia Pan
YHYanhua Han
Yanhua Han
TYTianjiao You
Tianjiao You
YZYang Zhang
Yang Zhang
Polycystic ovary syndrome (PCOS) is a touchy clinical and public health problem worldwide, which adversely affects women’s health and health-related comorbidities for lifetime, and represents a tremendous burden for both the family of the patient and for society. According to the diagnostic criteria used and the population studied, the prevalence rate of PCOS is between 6% and 21%. However, current conventional modern medicines for PCOS are only moderately effective at controlling the signs and symptoms, while they are not thoroughly able to prevent complications. Therefore, many patients have turned to complementary and alternative medical (CAM) treatments. CAM use is wide spread among patients with PCOS, and more than 70% of patients use CAM at one point during their diseases. The patients’ primary motivations include dissatisfaction with available medications, perceive higher risk of drug side effects and crushing health burden and economic costs, desire for symptom relief, pursuit of shortening the course of disease, and the belief that CAM therapy is in accordance with the patients’ values and beliefs. At present, several CAM methods have been used in women with PCOS, which has achieved obvious effects. However, biologically plausible mechanisms of the action of traditional Chinese medicine- (TCM-) associated CAM for PCOS have not been systematically reviewed. This review briefly summarizes the current progress of the impact of herbal medicine on the outcomes of PCOS and introduces the mechanisms.

29 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYang Zhang
Yang Zhang
FJFangfang Jin
Fangfang Jin
XWXing Wei
Xing Wei
QJQiuyu Jin
Qiuyu Jin
JXJingri Xie
Jingri Xie
WSWenjuan Shen
Wenjuan Shen
Objectives: This meta-analysis aimed to assess the effectiveness and safety of Chinese herbal medicine (CHM) in treating chronic fatigue syndrome (CFS).Methods: Nine electronic databases were searched from inception to May 2022. Two reviewers screened studies, extracted the data, and assessed the risk of bias independently. The meta-analysis was performed using the Stata 12.0 software.Results: Eighty-four RCTs that explored the efficacy of 69 kinds of Chinese herbal formulas with various dosage forms (decoction, granule, oral liquid, pill, ointment, capsule, and herbal porridge), involving 6,944 participants were identified. This meta-analysis showed that the application of CHM for CFS can decrease Fatigue Scale scores (WMD: –1.77; 95%CI: –1.96 to –1.57; p < 0.001), Fatigue Assessment Instrument scores (WMD: –15.75; 95%CI: –26.89 to –4.61; p &lt; 0.01), Self-Rating Scale of mental state scores (WMD: –9.72; 95%CI:–12.26 to –7.18; p &lt; 0.001), Self-Rating Anxiety Scale scores (WMD: –7.07; 95%CI: –9.96 to –4.19; p < 0.001), Self-Rating Depression Scale scores (WMD: –5.45; 95%CI: –6.82 to –4.08; p < 0.001), and clinical symptom scores (WMD: –5.37; 95%CI: –6.13 to –4.60; p < 0.001) and improve IGA (WMD: 0.30; 95%CI: 0.20–0.41; p &lt; 0.001), IGG (WMD: 1.74; 95%CI: 0.87–2.62; p &lt; 0.001), IGM (WMD: 0.21; 95%CI: 0.14–0.29; p &lt; 0.001), and the effective rate (RR = 1.41; 95%CI: 1.33–1.49; p &lt; 0.001). However, natural killer cell levels did not change significantly. The included studies did not report any serious adverse events. In addition, the methodology quality of the included RCTs was generally not high.Conclusion: Our study showed that CHM seems to be effective and safe in the treatment of CFS. However, given the poor quality of reports from these studies, the results should be interpreted cautiously. More international multi-centered, double-blinded, well-designed, randomized controlled trials are needed in future research.Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022319680], identifier [CRD42022319680].

15 May 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WSWenjuan Shen
Wenjuan Shen
BJBao Jin
Bao Jin
YHYaguang Han
Yaguang Han
HWHongwei Wang
Hongwei Wang
HJHuan Jiang
Huan Jiang
YZYang Zhang
Yang Zhang
Objective. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. As a traditional medicine, Salvia miltiorrhiza (S. miltiorrhiza) has been widely used in the treatment of many gynecological diseases, but the efficacy of S. miltiorrhiza in women with PCOS has not been assessed. The purpose of this systematic review and meta-analysis was to evaluate the effectiveness and safety of S. miltiorrhiza in women with PCOS. Methods. We conducted searches in PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure, the Wanfang Database, the Chinese Scientific Journal Database, and the Chinese BioMedical database from inception to December 23, 2020, to identify studies that met the inclusion criteria. The quality of the evidence was estimated using the Cochrane Reviewer Handbook 5.0.0, and the meta-analysis was performed using RevMan 5.3.5 software. Results. Six randomized controlled trials (RCTs) involving 390 patients with PCOS were included. The studies suggested that S. miltiorrhiza extract combined with letrozole (LET) was more effective in improving pregnancy rate (RR: 2.60, 95% CI: 1.06 to 6.39, ) compared to LET alone. S. miltiorrhiza extract was associated with decreased fasting blood glucose (MD: –0.25, 95% CI: –0.37 to –0.13, ), fasting insulin (MD: –1.16, 95% CI: –1.74 to –0.58, ), total cholesterol (TC) (MD: –0.58, 95% CI: –0.72 to –0.43, ), and triglycerides (TG) (MD: –0.31, 95% CI: –0.35 to –0.26, ) compared with placebo, but not with improvements in body mass index or waist-to-hip ratio (MD: –1.41, 95% CI: –4.81 to 2.00, ; MD: –0.02, 95% CI: –0.05 to 0.01, , respectively). There was a significant difference between S. miltiorrhiza extract combined with cyproterone acetate (CPA) and CPA alone in terms of decreasing TC (MD: –0.77, 95% CI: –0.89 to –0.65, ), TG (MD: –0.43, 95% CI: –0.65 to –0.20, ), and low-density lipoprotein cholesterol (MD: –0.49, 95% CI: –0.66 to –0.33, ) and increasing high-density lipoprotein cholesterol (MD: 0.30, 95% CI: 0.20, 0.40, ). In addition, S. miltiorrhiza extract also decreased testosterone, follicle-stimulating hormone, and luteinizing hormone. The studies did not mention any adverse events with S. miltiorrhiza extract. Conclusion. The current studies indicate that S. miltiorrhiza has beneficial effects on reproduction and glucose and lipid metabolism in patients with PCOS, and it is generally safe for clinical application. However, more prospective RCTs with large samples, multiple centers, and longer intervention duration are needed in the future to obtain more reliable conclusions.

6 June 2023 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
YZYang Zhang
Yang Zhang
FJFangfang Jin
Fangfang Jin
YWYuan Wu
Yuan Wu
BWBingyu Wang
Bingyu Wang
JXJingri Xie
Jingri Xie
WSWenjuan Shen
Wenjuan Shen
Gamma-glutamyl transpeptidase to platelet ratio (GPR) is an inflammatory index and has been used as a prognostic index for a variety of tumors. However, the association between GPR and hepatocellular carcinoma (HCC) still remained controversial. Therefore, we performed a meta-analysis to determine the prognostic impact of GPR on HCC patients. PubMed, Embase, Cochrane Library, Web of Science, the Chinese National Knowledge Infrastructure, Wanfang Database, Chinese VIP Database, the US Clinical Trials Registry, and the Chinese Clinical Trials Registry were searched from inception to December 2022. A hazard ratio (HR) with a 95% confidence interval (CI) was used to evaluate the association between preoperative GPR and the prognosis of HCC patients. Ten cohort studies including 4706 HCC patients were identified. This meta-analysis showed that higher GPRs were closely related to worse overall survival (HR: 1.79; 95% CI: 1.35–2.39; P < 0.001; I 2 = 82.7%), recurrence-free survival (HR: 1.30; 95% CI: 1.16–1.46; P < 0.001; I 2 = 0%), and disease-free survival (HR: 1.84; 95% CI: 1.58–2.15; P < 0.001; I 2 = 25.4%) in patients with HCC. This meta-analysis suggests that preoperative GPR appears to be significantly associated with the prognosis of HCC patients who have undergone surgery and may be an effective prognostic marker. Trial registration: PROSPERO: CRD42021296219.

24 August 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
BJBao Jin
Bao Jin
YZYang Zhang
Yang Zhang
ZZZongyu Zhang
Zongyu Zhang
GYGuorong Yang
Guorong Yang
YPYujia Pan
Yujia Pan
WSWenjuan Shen
Wenjuan Shen
Objective. Dingkun Pill (DKP) is a proprietary Chinese medicine that has been utilized for patients with gynecological diseases, and its clinical application has been widely accepted in China. However, the effects of DKP on reproduction and metabolism in women with polycystic ovary syndrome (PCOS) have never been systematically evaluated. Our objective was to evaluate the efficacy and safety of DKP in treating reproductive and metabolic abnormalities with PCOS. Methods. We searched in PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, VIP Database, and Chinese Biomedical Literature Database up until January 2022 to identify randomized controlled trials (RCTs). The methodological quality of the included RCTs was estimated using the Cochrane collaboration risk-of-bias instrument, and the meta-analysis was performed using RevMan. Results. A total of 22 RCTs (including 1994 participants) were identified. DKP, combined with ovulation-inducing drugs (OID) or combined oral contraceptives (COC) was superior to OID or COC alone in improving the pregnancy rate (relative risk (RR) 1.84, 95 CI 1.62 to 2.11 and RR 1.38, 95 CI 1.16 to 1.64, respectively), ovulation rate (RR 1.38, 95 CI 1.03 to 1.84 and RR 1.23, 95 CI 1.11 to 1.37, respectively), endometrial thickness (weighted mean difference (WMD) 2.50, 95 CI 1.91 to 3.09 and WMD 0.62, 95 CI 0.08 to 1.16, respectively), luteinizing hormone (WMD 1.93, 95 CI 2.80 to.07 and WMD 1.79, 95 CI 2.66 to0.92, respectively), and testosterone (standardized mean difference (SMD) 2.12, 95 CI 3.01 to1.24 and SMD 1.21, 95 CI 1.64 to0.78, respectively). DKP combined with COC led to a greater improvement in homeostasis model assessment-β (WMD 20.42, 95 CI 16.85 to 23.98) when compared with COC alone. There was a significant difference between DKP and COC in terms of decreasing total cholesterol (WMD 0.37, 95 CI 0.72 to0.02), triacylglycerol (WMD 0.85, 95 CI 1.50 to0.20), and free fatty acid (WMD 130.00, 95 CI 217.56 to42.22). However, DKP did not affect the follicle stimulating hormone, fasting blood glucose, fasting insulin, body mass index, waist-to-hip ratio, high-density lipoprotein cholesterol, or low-density lipoprotein cholesterol. Adverse reactions were more common in COC alone compared to DKP and COC in combination (RR 0.22, 95 CI 0.07 to 0.63). Conclusion. DKP shows promise in modifying reproductive and metabolic parameters in patients with PCOS and may be used as a primary choice in conventional or complementary therapies for PCOS. The quality of the evidence analyzed was suboptimal, and therefore, our results should be interpreted cautiously. More prospective large-scale and well-designed RCTs, as well as longer intervention durations are required in the future to draw more reliable conclusions.

15 June 2023 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
YZYang Zhang
Yang Zhang
XHXiaoyang Hu
Xiaoyang Hu
HZHuafeng Zhang
Huafeng Zhang
YPYujia Pan
Yujia Pan
ZZZongyu Zhang
Zongyu Zhang
WSWenjuan Shen
Wenjuan Shen